Abnormal vascular function in PR-interval prolongation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 7903272 Publication Model: Print Cited Medium: Internet ISSN: 1932-8737 (Electronic) Linking ISSN: 01609289 NLM ISO Abbreviation: Clin Cardiol Subsets: MEDLINE
    • Publication Information:
      Publication: Hoboken, NJ : John Wiley & Sons, Inc
      Original Publication: New York : G. Witzstrock
    • Subject Terms:
      Vasodilation*; Atrioventricular Block/*physiopathology ; Brachial Artery/*physiopathology ; Cardiovascular Diseases/*etiology; Aged ; Ankle Brachial Index ; Atrioventricular Block/complications ; Atrioventricular Block/diagnosis ; Brachial Artery/diagnostic imaging ; Cardiovascular Diseases/physiopathology ; Elasticity ; Electrocardiography ; Female ; Hong Kong ; Humans ; Linear Models ; Male ; Middle Aged ; Prognosis ; Pulsatile Flow ; Time Factors ; Ultrasonography
    • Abstract:
      Background: Underlying mechanisms of PR-interval prolongation leading to increased risk of adverse cardiovascular outcomes, including atrial fibrillation, are unclear. This study aims to investigate the relation between PR interval and changes in vascular function.
      Hypothesis: We hypothesize that there exists an intermediate pathological stage between electrocardiographic PR prolongation and adverse cardiovascular outcomes, which could be reflected by changes in surrogate measurements of vascular function.
      Methods: We recruited 88 healthy subjects (mean age 57.5 ± 9.8 y, 46% male) from a community-based health screening program who had no history of cardiovascular disease or diabetes mellitus. PR interval was determined from a resting 12-lead electrocardiogram. Vascular function was noninvasively assessed by flow-mediated dilation (FMD) using high-resolution ultrasound and brachial-ankle pulse wave velocity (PWV) using a vascular profiling system.
      Results: Only 3 subjects had a PR-interval length longer than the conventional cutoff of 200 ms. The PR-interval length was associated inversely with FMD (Pearson r = -0.30, P = 0.004) and positively with PWV (r = 0.40, P < 0.001). Adjusting for potential confounders, increased PR-interval length by each 25 ms was independently associated with reduced FMD by -1 unit (absolute %, B = -0.04 [95% confidence interval: -0.080 to -0.002, P = 0.040)] and increased PWV by +103 cm/second (B = +4.1 [95% confidence interval: 0.6-7.6, P = 0.023]).
      Conclusions: This study shows that PR-interval length, even in the conventionally normal range, is independently associated with endothelial dysfunction and increased arterial stiffness in healthy subjects free of atherosclerotic disease. This suggests the presence of a systemic, intermediate pathologic stage of the vasculature in PR prolongation before clinically manifest cardiovascular events, and could represent a mediating mechanism.
      (© 2011 Wiley Periodicals, Inc.)
    • References:
      Cardiology. 2007;108(1):35-9. (PMID: 16968988)
      Ann Intern Med. 1981 Jan;94(1):38-40. (PMID: 7447221)
      Chest. 1971 Jan;59(1):40-6. (PMID: 5099809)
      Atherosclerosis. 2007 May;192(1):197-203. (PMID: 16762358)
      Int J Clin Pract. 2009 Jul;63(7):982-5. (PMID: 19570114)
      Sports Med. 1998 Mar;25(3):139-48. (PMID: 9554025)
      Clin J Am Soc Nephrol. 2011 Jan;6(1):153-9. (PMID: 20829424)
      Am J Hypertens. 2009 Mar;22(3):319-24. (PMID: 19151694)
      J Am Coll Cardiol. 2010 Feb 23;55(8):771-3. (PMID: 20170815)
      Am J Cardiol. 2003 Jun 15;91(12):1519-22, A9. (PMID: 12804752)
      Clin Cardiol. 2009 Jan;32(1):37-42. (PMID: 19143003)
      J Hum Hypertens. 2005 Nov;19(11):855-9. (PMID: 16094406)
      Pacing Clin Electrophysiol. 2010 May;33(5):561-5. (PMID: 20059712)
      Curr Opin Rheumatol. 2009 Sep;21(5):478-82. (PMID: 19584727)
      J Cardiovasc Pharmacol. 2006 Apr;47(4):609-13. (PMID: 16680076)
      Neth J Med. 2005 Feb;63(2):59-63. (PMID: 15766009)
      Eur Heart J. 2008 Nov;29(22):2800-7. (PMID: 18812325)
      J Hypertens. 2010 Jan;28(1):2-8. (PMID: 19797978)
      Br Heart J. 1984 Feb;51(2):179-83. (PMID: 6197983)
      J Gerontol. 1990 May;45(3):M95-100. (PMID: 2335725)
      Eur Heart J. 2010 Dec;31(23):2854-61. (PMID: 20864485)
      Am J Cardiol. 2008 Aug 1;102(3):326-9. (PMID: 18638595)
      Lancet. 1987 Jan 24;1(8526):225-6. (PMID: 2880057)
      J Natl Med Assoc. 2004 Jun;96(6):756-60. (PMID: 15233485)
      Br J Clin Pharmacol. 1993 Aug;36(2):93-8. (PMID: 8398588)
      J Emerg Med. 1987;5(1):29-34. (PMID: 3584915)
      Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):360-8. (PMID: 21450646)
      Am J Clin Nutr. 2007 Oct;86(4):938-45. (PMID: 17921368)
      JAMA. 2009 Jun 24;301(24):2571-7. (PMID: 19549974)
      Eur Heart J. 1984 Jan;5(1):2-6. (PMID: 6705801)
      Eur Heart J. 1984 Mar;5 Suppl A:107-9. (PMID: 6373267)
      Hypertens Res. 2002 May;25(3):359-64. (PMID: 12135313)
      Stroke. 2009 Apr;40(4):1204-11. (PMID: 19213946)
      J Am Coll Cardiol. 2010 May 25;55(21):2299-307. (PMID: 20488299)
      Postgrad Med J. 1990 Feb;66(772):140-1. (PMID: 2349187)
    • Publication Date:
      Date Created: 20111014 Date Completed: 20120202 Latest Revision: 20240718
    • Publication Date:
      20240718
    • Accession Number:
      PMC6652440
    • Accession Number:
      10.1002/clc.20958
    • Accession Number:
      21994083